Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-24T12:39:49.068Z Has data issue: false hasContentIssue false
  • English
  • Français

Quantitative Motor Assessment in Myotonic Dystrophy

Published online by Cambridge University Press:  16 December 2016

J. Mathieu ,
H. Boivin  and
C.L. Richards
J. Mathieu*
Affiliation:
Neuromuscular Clinic, Centre de réadaptation en déficience physique, Jonquiére, QC, Canada Community Genomic Medicine Center, Montreal University, Montreal, QC, Canada
H. Boivin
Affiliation:
Neuromuscular Clinic, Centre de réadaptation en déficience physique, Jonquiére, QC, Canada
C.L. Richards
Affiliation:
Laval University, Quebec, QC, Canada
*
Service de Neurologie, CHU de la Milétrie 86021, Poitiers, France
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To establish baseline data, using a quantitative motor evaluation protocol, prior to a prospective longitudinal study of the natural history of muscular involvement in myotonic dystrophy (DM).

Design/Methods:

We conducted a cross-sectional study using a protocol consisting of manual muscle testing (MMT), quantitative muscle testing (QMT), and timed functional testing (TFT) on 50 definite DM patients (27 men, 23 women), aged 16 to 67 years. The relationships between MMT, QMT and TFT scores and disease duration were examined using linear regression analysis.

Results:

The muscle weakness was symmetric and the neck flexors and the distal muscles of upper and lower extremities were weaker than proximal muscles. Using MMT scores, the average strength decline was 0.95% per year and was similar for men and women. The strength decline was significantly more rapid for distal muscles than for proximal muscles. Quantitative muscle testing scores documented a strength decline per year of disease duration of 1.2-1.6% for the hip flexors and of 2.0-3.0% for the hand grip flexors.

Conclusions:

We observed significant linear relationships between the scores generated by this protocol and disease duration. These data illustrate the distal to proximal progression of muscular involvement in DM, a pattern of progression well-recognized by the clinicians. The follow-up assessment of a large DM cohort in a longitudinal study will establish whether this quantitative protocol provides sensitive measures of the disease progression.

Résumé:

RÉSUMÉ:Objectif:

Établir des données de base au moyen d'un protocole d'évaluation motrice quantitative avant d'entreprendre une étude longitudinale prospective sur l'histoire naturelle de l'atteinte musculaire dans la dystrophie myotonique (DM).

Plan et Méthodes:

Nous avons effectué une étude transversale en utilisant un protocole comprenant une évaluation musculaire manuelle (ÉMM), une évaluation musculaire quantitative (ÉMQ) et une évaluation fonctionnelle chronométrée (ÉFC) chez 50 patients atteints de DM (27 hommes et 23 femmes), âgés de 16 à 67 ans. La relation entre les scores de l'ÉMM, l'ÉMQ et l'ÉFC et la durée de la maladie a été analysée au moyen de l'analyse de régression linéaire.

Résultats:

La faiblesse musculaire était symétrique et les fléchisseurs du cou et les muscles distaux des extrémités supérieures et inférieures étaient plus faibles que les muscles proximaux. Selon les scores de l'ÉMM, la diminution moyenne de la force était de 0,95% par année, tant chez les hommes que chez les femmes. La diminution de la force des muscles distaux était significativement plus rapide que celle des muscles proximaux. Les scores de l'ÉMQ ont montré une diminution de la force de 1,2 à 1,6% au niveau des fléchisseurs de la hanche et de 2,0 à 3,0% pour les fléchisseurs des doigts, par année de durée de la maladie.

Conclusions:

Nous avons observé une relation linéaire significative entre les scores générés par ce protocole et la durée de la maladie. Ces données illustrent la progression distale à proximale de l'atteinte musculaire dans la DM, ce qui est bien connu des cliniciens. L'étude longitudinale d'une grande cohorte de patients atteints de DM établira si on peut obtenir des mesures sensibles de la progression de la maladie au moyen de ce protocole quantitatif.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 30 , Issue 2 , May 2003 , pp. 129 - 136
Copyright
Copyright © The Canadian Journal of Neurological 2003

References

REFERENCES

1. Harley, HG, Brook, JD, Rundle, SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355:545–546.Google Scholar
2. Harper, PS. Myotonic dystrophy. 3rd ed. London: W.B.Saunders,2001.Google Scholar
3. Mathieu, J, DeBraekeleer, M, Prévost, C. Genealogical reconstruction of myotonic dystrophy in the Saguenay-Lac-Saint-Jean area (Quebec, Canada). Neurology 1990;40:839–842.Google Scholar
4. Brooke, MH, Fenichel, GM, Griggs, RC, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91–103.Google Scholar
5. Munsat, TL, Andres, PL, Finison, L, Conlon, T, Thibodeau, L. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988;38:409–413.Google Scholar
6. Andres, PL, Finison, L, Conlon, T, Thibodeau, L, Munsat, TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988;38:405–408.Google Scholar
7. Pradas, J, Finison, L, Andres, PL, et al. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751–755.Google Scholar
8. Munsat, TL. Issues in clinical trial design 1: use of natural history controls. A protagonist view. Neurology 1996;47:S96–S97.Google Scholar
9. Tawil, R, McDermott, MP, Mendell, JR, et al. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. Neurology 1994;44:442–446.Google Scholar
10. The FSH-DY Group. A prospective quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997;48:38–46.Google Scholar
11. Mathieu, J, Boivin, H, Meunier, D, Gaudreault, M, Bégin, P. Assessment of a disease-specific impairment rating scale in myotonic dystrophy. Neurology 2001; 56(3):336–340.Google Scholar
12. Koch, MC, Grimm, T, Harley, HG, Harper, PS. Genetic risk for children of women with myotonic dystrophy. Am J Hum Genet 1991;48:1084–1091.Google Scholar
13. Appel, V, Stewart, SS, Smith, G, Appel, SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328–333.Google Scholar
14. Fisher, LD, Van Belle, G. Biostatistics. A methodology for the Health Sciences. John Wiley and Sons, New York, 1993.Google Scholar
15. SPSS Advanced and Professional Statistics 6.1., Chicago, IL. SPSS Inc., 1994.Google Scholar
16. Moxley, RT. Functional testing. Muscle Nerve 1990 (Suppl): S26–S29.Google Scholar
17. Mendell, JR, Florence, J. Manual muscle testing. Muscle Nerve 1990 (Suppl): S16–S20.CrossRefGoogle ScholarPubMed
18. Personius, KE, Pandya, S, King, WM, Tawil, R, McDermott, MP and the FSH DY Group. Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. Phys Ther 1994;74:253–263.Google Scholar
19. Johnson, ER, Abresch, RT, Carter, GT, et al. Profile of neuromuscular diseases: myotonic dystrophy. Am J Phys Rehabil 1995;74(Suppl 5):S104–S116.Google Scholar
20. FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. Neurology 1997;48:38–46.Google Scholar
21. Andres, PL, Hedlund, W, Finison, L, et al. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937–941.Google Scholar
22. Griggs, RC, Pandya, S, Florence, JM et al. Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 1989;39:219–222.Google Scholar
23. Lindeman, E, Leffers, P, Reulen, J, Spaans, F, Drukker, J. Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects. Clin Rehabil 1998;12:127–135.Google Scholar
24. Orndahl, G, Grimby, G, Grimby, A, Johansson, G, Wilhelmsen, L. Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study. J Intern Med 1994;235:205–210.CrossRefGoogle ScholarPubMed